Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies

• Published in: Scientific reports 2020-10, Vol.10 (1), p.16357, Article 16357
• Main Authors: Cao, Lei, Wang, Fei, Du, Xin-Yi, Zhu, Hua-Yuan, Wang, Li, Xu, Wei, Li, Jian-Yong, Fan, Lei
• Format: Article
• Language: English
• Subjects: 631/67/1990/283; 631/67/580; Adult; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Autoimmune diseases; Bronchopulmonary infection; Chemotherapy; Chronic lymphocytic leukemia; Diagnosis; Female; Fludarabine; Humanities and Social Sciences; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Lymphatic leukemia; Male; Medical prognosis; Methylprednisolone; Middle Aged; Monoclonal antibodies; multidisciplinary; Paraneoplastic Syndromes - diagnosis; Paraneoplastic Syndromes - drug therapy; Pemphigus; Pemphigus - diagnosis; Pemphigus - drug therapy; Prednisone; Prednisone - therapeutic use; Prognosis; Retrospective Studies; Rituximab; Rituximab - therapeutic use; Science; Science (multidisciplinary); Secondary infection; Skin diseases; Targeted cancer therapy; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-73131-y

Paraneoplastic pemphigus (PNP) is a severe autoimmune syndrome commonly triggered by neoplasms. The prognosis of CLL-associated PNP is dismal due to its refractory course and secondary infection and no standard treatment was recommended. We retrospectively reported six CLL with PNP cases from 842 cases of CLL including diagnosis, treatment and prognosis. The median time between the initial of CLL to PNP was 36 months while the median overall survival from the diagnosis of PNP was 26 months. And three cases died of lung infection while 5 developed pulmonary symptoms. And 5 cases received fludarabine-based chemotherapy before developing PNP, which suggesting fludarabine was one of potential causes of PNP. For the treatment, five patients were rescued by combined regimens including rituximab, methylprednisolone, immunoglobulin, fresh frozen plasma and the last received ibrutinib combined with short-term prednisone. Fludarabine-based regimen may be one of the potential causes of PNP. The combined regimen might shed a new light, while ibrutinib is a promising drug for CLL with PNP, but needs much more evidence. PNP should be carefully treated to guide early diagnosis and intervention for a better prognosis.